Greater Occipital Nerve Block for Migraine Prophylaxis

Completed · Phase 4 · Has a placebo group

Conditions studied: Migraine Headache

In brief

Migraine is a common neurological condition that can be disabling, particularly if chronic. Greater occipital nerve (GON) block has been utilized for decades for the treatment of migraine in the absence of a single randomized, placebo-controlled trial documenting its effectiveness. Hypothesis: Greater occipital nerve block reduces the frequency of days with moderate or severe headache in patients with episodic or chronic migraine.

Key facts

Study ID

NCT00915473

Run by

Mayo Clinic

People needed

70

Starts

2009-06-01

Expected to finish

2013-01-01

Last updated by the study team

2014-03-20

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects meet diagnostic criteria for episodic migraine or chronic migraine according to the International Headache Classification II (ICHD-II)
• Migraine sufferers who experience at least 1 attack per week
• Able to read and understand the requirements of the study, abide by any restrictions, and return for the required examinations
• Able and willing to sign an informed consent statement
• Subjects must be in generally good health as confirmed by medical history, medication review, baseline physical examination, vital signs and clinical laboratory evaluations.

You may not qualify if…

• Subjects with continuous headache (no headache free periods)
• Subjects using maintenance opioid medication
• Subjects who have started a medication with prophylactic migraine efficacy within the past 2 months
• Known hypersensitivity or allergic reaction to any of study ingredients (lidocaine, bupivicaine, any local anesthetics, and corticosteroids) or betadine.
• Use of any investigational medication within 90 days of the initial screening visit and/or concurrent enrolment in an investigational study
• Injection site infection or systemic infection at the injection visit (afebrile at time of injection)
• Presence of cranial bone defect
• Subjects with chronic cluster headache, new daily persistent headache, hemicrania continua, or chronic tension type headache
• Subjects with a history of an unstable medical condition (e.g. cardiovascular, hepatic, renal, endocrine) that may impair their reliable participation in the study or necessitate the use of medications not permitted in this study
• Subjects with a history (within the past 6 months) of a major psychiatric disorder that in the opinion of the investigator may preclude the subject from completed the requirements of the study
• Female subjects who are pregnant or nursing
• Subjects with a history of drug or alcohol abuse within the past 2 years
• Subjects with a history of poor compliance with past drug therapies, as judged by the investigator.

Where it is running

• Mayo Clinic — Phoenix, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.